Udvalget for Humanmedicinske Lægemidler (CHMP) konkluderede, at Revatio udgør et alternativ til behandling af PAH.
The Committee for Medicinal Products for Human Use (CHMP) concluded that Revatio provides an alternative treatment option for PAH.